Researchers identified the primary actors circ2082 (a circular RNA) and RBM3 (an RNA-binding protein), which form a complex with DICER to stay in the nucleus of glioblastoma cells, thereby destroying the microRNAome in the cytoplasm.
Now, a new study overturns the long-standing view that mRNA in stress particles can indeed make proteins. The related research results are published in the journal Cell with the title of "Single-Molecule Imaging Reveals Translation of mRNAs Localized to Stress Granules".
The study suggests that blocking the effect of ATM/ATR on SerRS, for instance, through the expression of a phosphorylation-deficient form of SerRS, can act as a major inhibitor of multiple hypoxia response pathways to effectively inhibit angiogenesis.
The results support a model where RNA provides positive and negative feedback on transcription by regulating electrostatic interactions in transcriptional condensates.
In this study, researchers performed small and long RNA sequencing (RNA-seq) of whole-blood samples collected from ischemic stroke patients 2 days after stroke onset, and mined RNA-seq datasets of blood cell transcripts.
In this paper, we review the new achievements made by scientists in the field of miRNA research in recent years.
In this paper, we review the new achievements made by scientists in the field of miRNA research in recent years.
Recently, researchers from the University of Groningen, the International Institute of Molecular and Cell Biology in Warsaw, and Leiden University studied the RNA genome structure of SARS-CoV-2 coronavirus in detail. The RNA structure is a potential target for the development of antiviral drugs. The results were published in the journal Nucleic Acid Research.
Recently, in a research report published in the international journal Nature, scientists from Julius-Maximilians-Universität Würzburg identified a new ribozyme that catalyzes the site-specific installation of 1-methyladenosine in a substrate RNA, using O6-methylguanine as a small-molecule cofactor. The ribozyme displays a broad RNA-sequence scope, as exemplified by site-specific adenosine methylation in various RNAs.
Researchers from Massachusetts Institute of Technology (MIT) have now greatly increased the amount of information collected from each cell by modifying the commonly used Seq-Well technique. Researchers call Seq-Well S3 (for "Second-Strand Synthesis"), which incorporates the use of a randomly primed second-strand synthesis after reverse transcription to append a second oligonucleotide handle for whole transcriptome amplification (WTA).
Recently, in a research report entitled "Treating Cystic Fibrosis with mRNA and CRISPR" published in the international journal Human Gene Therapy, scientists from Georgia Institute of Technology have revealed how to use mRNA therapy and CRISPR technology to treat patients with cystic fibrosis.
In a new study, the researchers confirmed that a dose of RNA-targeting CRISPR-Cas9 (RCas9) gene therapy can degrade toxic RNA and almost completely reverse the symptoms of a mouse model of myotonic dystrophy.
To overcome these constraints, Wu Hao Laboratory of the University of Pennsylvania has developed single-cell metabolically labeled new RNA tagging sequencing (scNT-seq), a high-throughput and UMI-based scRNA-seq method, to detect the dynamic changes of single-cell mRNA.
The study identified the predicted deadenylase angel homolog 2 (ANGEL2) as a human phosphatase that converts 2',3'-cyclic phosphates into 2',3'-OH nucleotides. ANGEL2 modulates levels of mature tRNAs and XBP1 mRNA during pre-tRNA processing in vitro and in the unfolded protein response (UPR), respectively.
Recently, research led by biomedical scientists from City University of Hong Kong (CityU) has developed CRISPR-assisted RNA-protein interaction detection method (CARPID), which leverages CRISPR-CasRx-based RNA targeting and proximity labeling to identify binding proteins of specific long non-coding RNAs (lncRNAs) in the native cellular context.
In a recent study, scientists have successfully edited RNA in living animals so that the repaired RNA can correct mutations in proteins, thus improving the neurasthenia caused by Rett syndrome. The results were published in the recent journal Cell Reports.
mRNA-based vaccines are a promising platform with the potential to be highly versatile, potent, scalable, streamlined, inexpensive, and cold-chain free. More importantly, mRNA-based vaccines may fill the gap between emerging pandemic infectious diseases and a rapid, abundant supply of effective vaccines.
In this review, the researchers revealed the epitranscriptomic pathways of RNA involved in cancer, and described its biological function and its relationship with disease.
